Policy number:	
Effective date:	

SPECIALTY GUIDELINE MANAGEMENT

ORFADIN (nitisinone) NITYR (nitisinone)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Orfadin is indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

Nityr is indicated for the treatment of patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

Authorization of 6 months may be granted for treatment of hereditary tyrosinemia type 1 (HT-1) when the diagnosis is confirmed by biochemical testing (e.g., detection of succinylacetone in urine) or DNA testing.

If the patient is requesting Orfadin (nitisinone), they must have a documented failure, or intolerance to Nityr (nitisinone) tablets.

III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCE

- 1. Orfadin [package insert]. Ardmore, PA: Sobi, Inc; September 2017.
- 2. Nityr [package insert]. Cambridge, United Kingdom: Cycle Pharmaceuticals Ltd.; July 2017.

Orfadin-Nityr SGM P2018.docx

pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2018 CVS Caremark. All rights reserved.



This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of